Information on the DNP-Doctorate of Nursing Practice

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 11
Volume 15
Issue 11

The new Doctor of Nursing Practice (DNP) degree is meant to be to nursing clinical practice what the PhD is to nursing research, Sharon Krumm, RN, PhD, said at the Oncology Nursing Society 31st Annual Congress (abstract 34).

BOSTON--The new Doctor ofNursing Practice (DNP) degree is meantto be to nursing clinical practice what thePhD is to nursing research, SharonKrumm, RN, PhD, said at the OncologyNursing Society 31st Annual Congress(abstract 34). Dr. Krumm is administratorand director of nursing at the SidneyKimmel Comprehensive Cancer Centerat Johns Hopkins Hospital.

Dr. Krumm said that the DNP is intendedto provide "clinical, organizational,economic, and leadership skillsneeded to critique scientific findings anddesign care delivery programs to addresslocal needs and effect positive health careoutcomes."

The DNP curriculum has three parts:core essentials; Advanced Nursing Practicecore and differentiated competencies based on direct care or the indirectinfluence of clinical outcomes; and specialtycompetencies and content definedby specialty nursing organizations.

Dr. Krumm said that this new degreeis designed, in part, to increase the numberof faculty available at schools ofnursing, enabling them to increase enrollmentin schools of nursing and toattract individuals who might not otherwiseconsider nursing as a career. Enrollmentinto a number of nursing programsis currently limited because of a facultyshortage, she said.

Meanwhile, the projected need for staffnurses in the year 2020 is expected toexceed the supply by 20%, and vacancyrates will increase from 6% today to 29%in 2020. "The demand for health serviceswill increase by 40%, while the numberof nurses will increase by only 6%," Dr.Krumm said.

Another question is how the DNP will affectrelationships with other professions."The American Medical Associationtask force on the scopeof practice partnerships seeksto limit nonphysician practices.Would the DNPchange this?" Dr. Krummasked.

The continuing turf disputeis highlighted by the AmericanMedical Association's "Policy RegardingSupervision of Medical Care Delivered by Advanced Practice Nurses inIntegrated Practice." This documentstates that physicians mustretain authority for patientcare in any team care arrangement;that medical societiesshould lobby legislatures andlicensing boards "to preventdilution of the authority ofphysicians to lead the health careteam"; that only physicians shouldbe able to independently prescribe drugs;and that physicians should run the qualitycontrol programs for nonphysiciansdelivering medical care in integratedpractices. Dr. Krumm commented:"Consensus in the academic and clinicalcommunities about the DNP has yet tobe achieved. Role clarity, both within theprofession and for patients and society,is essential. We need to remember that ittakes courage to change, and it takescourage to resist change if that is theappropriate stance."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content